92 related articles for article (PubMed ID: 20872144)
1. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity.
Basso M; Modoni A; Spada D; Cassano A; Schinzari G; Lo Monaco M; Quaranta D; Tonali PA; Barone C
Cancer Chemother Pharmacol; 2011 May; 67(5):1179-87. PubMed ID: 20872144
[TBL] [Abstract][Full Text] [Related]
2. The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?
Park SB; Lin CS; Krishnan AV; Kiernan MC
Cancer Chemother Pharmacol; 2011 May; 67(5):1189-90; author reply 1191-2. PubMed ID: 21327679
[No Abstract] [Full Text] [Related]
3. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
5. Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy.
Argyriou AA; Antonacopoulou AG; Scopa CD; Kottorou A; Kominea A; Peroukides S; Kalofonos HP
Oncology; 2009; 77(3-4):254-6. PubMed ID: 19738391
[TBL] [Abstract][Full Text] [Related]
6. Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Exp Neurol; 2011 Jan; 227(1):120-7. PubMed ID: 20965170
[TBL] [Abstract][Full Text] [Related]
7. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.
Lehky TJ; Leonard GD; Wilson RH; Grem JL; Floeter MK
Muscle Nerve; 2004 Mar; 29(3):387-92. PubMed ID: 14981738
[TBL] [Abstract][Full Text] [Related]
9. Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin.
McHugh JC; Tryfonopoulos D; Fennelly D; Crown J; Connolly S
Eur J Cancer Care (Engl); 2012 Nov; 21(6):782-9. PubMed ID: 22594346
[TBL] [Abstract][Full Text] [Related]
10. Possible association of CAG repeat polymorphism in KCNN3 encoding the potassium channel SK3 with oxaliplatin-induced neurotoxicity.
Anon B; Largeau B; Girault A; Chantome A; Caulet M; Perray C; Moussata D; Vandier C; Barin-Le Guellec C; Lecomte T
Cancer Chemother Pharmacol; 2018 Jul; 82(1):149-157. PubMed ID: 29774408
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy.
Sittl R; Carr RW; Fleckenstein J; Grafe P
Neurotoxicology; 2010 Dec; 31(6):694-700. PubMed ID: 20670646
[TBL] [Abstract][Full Text] [Related]
12. Acute oxaliplatin-induced peripheral nerve hyperexcitability.
Wilson RH; Lehky T; Thomas RR; Quinn MG; Floeter MK; Grem JL
J Clin Oncol; 2002 Apr; 20(7):1767-74. PubMed ID: 11919233
[TBL] [Abstract][Full Text] [Related]
13. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
Lersch C; Schmelz R; Eckel F; Erdmann J; Mayr M; Schulte-Frohlinde E; Quasthoff S; Grosskreutz J; Adelsberger H
Clin Colorectal Cancer; 2002 May; 2(1):54-8. PubMed ID: 12453338
[TBL] [Abstract][Full Text] [Related]
14. Dual contribution of NR2B subunit of NMDA receptor and SK3 Ca(2+)-activated K+ channel to genetic predisposition to anorexia nervosa.
Koronyo-Hamaoui M; Frisch A; Stein D; Denziger Y; Leor S; Michaelovsky E; Laufer N; Carel C; Fennig S; Mimouni M; Ram A; Zubery E; Jeczmien P; Apter A; Weizman A; Gak E
J Psychiatr Res; 2007; 41(1-2):160-7. PubMed ID: 16157352
[TBL] [Abstract][Full Text] [Related]
15. SK3 Gene Polymorphism Is Associated with Taxane Neurotoxicity and Cell Calcium Homeostasis.
Rua C; Guéguinou M; Soubai I; Viel E; Potier-Cartereau M; Chantome A; Barbe C; Bougnoux P; Barin-Le Guellec C; Vandier C
Clin Cancer Res; 2018 Nov; 24(21):5313-5320. PubMed ID: 30037821
[No Abstract] [Full Text] [Related]
16. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience.
Polyzos A; Tsavaris N; Gogas H; Souglakos J; Vambakas L; Vardakas N; Polyzos K; Tsigris C; Mantas D; Papachristodoulou A; Nikiteas N; Karavokyros JG; Felekouras E; Griniatsos J; Giannopoulos A; Kouraklis G
Oncology; 2009; 76(1):36-41. PubMed ID: 19033714
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin-induced lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Oncology; 2009; 77(6):342-8. PubMed ID: 20016227
[TBL] [Abstract][Full Text] [Related]
18. Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Antonacopoulou AG; Alberti P; Briani C; Bruna J; Velasco R; Anastopoulou GG; Park SB; Cavaletti G; Kalofonos HP
J Peripher Nerv Syst; 2019 Dec; 24(4):298-303. PubMed ID: 31486252
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway.
Gamelin L; Capitain O; Morel A; Dumont A; Traore S; Anne le B; Gilles S; Boisdron-Celle M; Gamelin E
Clin Cancer Res; 2007 Nov; 13(21):6359-68. PubMed ID: 17975148
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin and axonal Na+ channel function in vivo.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Clin Cancer Res; 2006 Aug; 12(15):4481-4. PubMed ID: 16899592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]